For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

to supplement or replace the deficient thyroid hormones in the body," said Dr Harshal Chaudhari, Head Medical Affairs, CM&E Merck Healthcare. Levothyroxine is a synthetic form of the thyroid ...

This can occur due to the following scenarios: According to Dr. Harshal Chaudhari - Head Medical Affairs – CM&E Merck Healthcare India Associate Director – Cardiology & Thyroid, Merck ...

German Merck said it plans to combine its scientific ... They will also focus on diabetes, thyroid disorders and cardiovascular diseases, as well as oncology including metastatic colorectal ...